Triple Therapy in Metastatic CRC With BRAF Mutations: The New Standard of Care?

(MedPage Today) -- SAN FRANCISCO -- First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant metastatic colorectal cancer (mCRC), according to the BREAKWATER trial.
The study looked...